article thumbnail

Doctor Sues DEA for Right to Give Psilocybin to Ailing Patients

Project CBD

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 344
article thumbnail

DEA loosens rules on prescription CBD drug Epidiolex

Leafly

Prescription CBD tincture Epidiolex is coming to more patients. The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly. Cost: $32,500 per year.

DEA 128
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

Food and Drug Administration (FDA) approved Epidiolex, a drug containing Cannabidiol (CBD). Epidiolex is the first drug the FDA has approved that contains a substance derived from marijuana, and it is also the first drug approved by the FDA to be used to treat patients with Dravet syndrome. On Monday, the U.S.

DEA 113
article thumbnail

DEA Promises Progress on Federal Cultivation Applications, But Provides No Timetable for Action

NORML

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 165
article thumbnail

The Key Differences Between CBD and THC You Need to Know

United Patients Group

CBD and THC are two natural substances found in the cannabis plant. Defining CBD and THC. CBD is derived from hemp or marijuana plants, both species of Cannabis Sativa. Hemp-derived CBD must have a THC concentration of 0.3 Hemp-derived CBD must have a THC concentration of 0.3 Psychoactive Effects of CBD and THC.

THC 116
article thumbnail

Doctor Sues DEA for Right to Give Psilocybin to Dying Patients

Project CBD

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 150
article thumbnail

Scientists Sue DEA as it Drags its Feet and Hampers Cannabis Research

WeedAdvisor

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.

DEA 111